This clinical trial is focused on treating a specific type of leukemia called Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL), particularly a subtype known as BCR/ABL1-like ALL. The study involves using a medication called Ponatinib, which is a type of drug known as a tyrosine kinase inhibitor, in combination with various chemotherapy drugs. The chemotherapy drugs used in this study include Dexamethasone Disodium Phosphate, Vincristine Sulfate, Mercaptopurine, Filgrastim, Idarubicin Hydrochloride, Lenograstim, Prednisone, Cyclophosphamide, Cytarabine, Folinic Acid, Methotrexate, and Methylprednisolone Sodium Succinate. Some patients may receive a placebo as part of the study.

The purpose of the study is to see how well this combination of treatments works in helping patients achieve remission, which means the disease is no longer detectable, even at a very detailed level. The study will follow patients over a period of time to monitor their response to the treatment. Participants will receive the treatment in cycles, and their health will be closely monitored throughout the study to assess the effectiveness and safety of the treatment.

During the study, patients will receive the treatment through different methods, such as oral tablets or injections, depending on the specific medication. The study aims to improve the percentage of patients who achieve remission and to understand the long-term outcomes of using Ponatinib with chemotherapy. The study will also track any side effects or adverse events that may occur during the treatment. The overall goal is to find a more effective treatment approach for patients with this type of leukemia.